Bayer’s proposed $7.25 billion Roundup settlement could be resolved before Christmas
Key Facts
Bayer Chief Executive Bill Anderson expects a decision before Christmas on a proposed settlement worth up to $7.25 billion for Roundup herbicide cases, in a move that could address tens of thousands of lawsuits linked to the product. The agreement is still under review by a judge in a Missouri state court in St. Louis, Reuters reported. Anderson said a decision could come "any week now," suggesting a court ruling is close. Bayer faces about 65,000 claims in U.S. state and federal courts from people who say they developed cancer after using the herbicide at home or at work. The decision matters to the company because the litigation has cost it billions of dollars and weighed on its stock, according to a Reuters report published on October 30.
The proposed settlement provides for funding of up to $7.25 billion through capped annual payments that decline over time, over a period of up to 21 years, according to a Bayer disclosure. The agreement targets a group of people who were exposed to Roundup before its effective date and were diagnosed, or will be diagnosed, with non-Hodgkin lymphoma within 16 years of that date. The settlement does not take effect with an initial approval decision; the disclosure says it requires final approval and the exhaustion of appeals. The company said the agreement includes no admission of liability or wrongdoing and is intended to substantially reduce litigation related to its product. The funding amount and duration therefore remain part of proposed terms tied to the judicial review process, while litigants await the court's decision on them.
Anderson said the number of individual cases would be much lower after the settlement if the process proceeds to take effect. The effort to address the lawsuits comes as Bayer says decades of studies have shown that glyphosate, the active ingredient in Roundup, is safe and does not cause cancer, an argument it uses to contest plaintiffs' claims. By contrast, the claims are based on allegations by people who say they developed cancer after using the product. The proposed agreement does not automatically close every individual case; Anderson's statement points to a sharp decline in the number after the settlement, while the company still faces about 65,000 claims. The process puts a broad class settlement alongside the continuation of disputes that the agreement does not cover or that remain outside its terms.
Bayer places the Roundup litigation in a legal context that changed during the year, saying the anticipated settlement decision follows its victory before the U.S. Supreme Court in June. On June 25, 2026, the court ruled 7 to 2 in favor of Monsanto in the Durnell case, addressing whether federal law preempts state-level failure-to-warn claims. Bayer later moved its U.S. Roundup business into a unit it called Ruveon and internally separated it from the rest of the company, Reuters reported. In a third-quarter update, Anderson said the final approval hearing for the settlement was held in September and that the company remained confident in the proposed agreement. He added that Bayer sees combining the settlement with the Supreme Court ruling as the best way to contain the litigation.
The wait for a ruling coincided with Bayer reporting quarterly results showing group sales rose to 10.053 billion euros in the third quarter of 2026, up a reported 4.1%, or 1.9% on a currency- and portfolio-adjusted basis. Earnings before interest, taxes, depreciation and amortization, before special items, came to 1.615 billion euros, an increase of 6.9% year over year. The company also raised its 2026 forecast for this measure to a currency-adjusted range of 9.8–10.3 billion euros, from a previous range of 9.6–10.1 billion euros. In early Frankfurt trading on November 3, Bayer shares rose 2%, according to Reuters' report on the results. The judge's decision on the settlement, which Anderson said could come "any week now," remains the next defined milestone in the litigation.